Ligand generated total revenues and income of 59666000 in Q4 2025, up 39% year-over-year, driven by a 45% increase in royalties, resulting in GAAP net income of 44784000 and adjusted net income of 42663000.

Ligand’s Q3 2025 results showed a dramatic increase in total revenue and profitability, boosted by a $28.6M gain on the sale of its Pelthos business and a $24.5M out-license of Zelsuvmi. Royalties and Captisol sales also improved year-over-year.

Ligand Pharmaceuticals reported a robust second quarter in 2025, with total revenues increasing by 15% year-over-year, primarily due to a 57% surge in royalty revenue. The company also significantly raised its full-year 2025 revenue and adjusted EPS guidance, reflecting continued strength in its commercial-stage royalty portfolio and key partnership milestones.

Ligand Pharmaceuticals reported a significant increase in total revenues and other income for the first quarter of 2025, primarily due to a 44% growth in royalty revenue. Despite the revenue growth, the company reported a GAAP net loss, largely influenced by a one-time charge related to a royalty financing agreement. Ligand reaffirmed its full-year 2025 financial guidance.

Ligand Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by royalty revenue growth and strategic investments. The company is reaffirming its 2025 financial guidance, expecting revenue between $180 million and $200 million and adjusted EPS between $6.00 and $6.25.

Ligand reported a successful Q3 2024, driven by a 58% increase in revenue, primarily due to royalty revenue and milestone payments, leading to increased full-year financial guidance. Several key portfolio events, including successful commercial launches and FDA approvals, are expected to drive future revenue growth.

Ligand reported a strong second quarter with total revenues of $41.5 million, driven by increased royalty revenue and milestone payments. The company added four new commercial-stage programs and reaffirmed its 2024 financial guidance.

Ligand Pharmaceuticals reported a decrease in total revenues to $31.0 million compared to $44.0 million in the same period last year, while royalties increased to $19.1 million. Net income from continuing operations was $86.1 million, or $4.75 per diluted share, primarily due to gains from short-term investments associated with Viking Therapeutics stock of $60.0 million.

Ligand Pharmaceuticals reported Q4 2023 total revenues of $28.1 million. Net income from continuing operations for the fourth quarter of 2023 was $18.2 million, or $1.03 per diluted share, compared to a net loss of $14.5 million, or $0.86 per share, for the same period in 2022.

Ligand Pharmaceuticals reported strong Q3 2023 financial results with total revenues of $32.9 million, and royalties of $23.9 million. The company actively executed its investment strategy, investing over $75 million in Tolerance, Ovid, Novan and Primrose transactions. Ligand is increasing its 2023 revenue guidance to be in the range of $126 million to $129 million and is raising adjusted EPS guidance to $5.25 to $5.40.

Ligand reported Q2 2023 revenues of $26.4 million. Royalties were $20.4 million, and core Captisol sales were $5.2 million. Net income from continuing operations was $2.3 million, or $0.13 per diluted share, and adjusted net income from continuing operations was $25.1 million, or $1.42 per diluted share. The company had $219 million in cash, cash equivalents and short-term investments as of June 30, 2023.

Ligand Pharmaceuticals reported a strong start to 2023 with $44.0 million in first quarter revenues, driven by royalty revenue growth and the approval milestone from Travere's FILSPARI. The company increased its 2023 revenue and EPS guidance.

Ligand reported a net loss of $14.5 million for Q4 2022, with total revenues of $50.4 million. The results were impacted by a $24.8 million deferred tax asset valuation allowance and a $44.2 million non-cash gain from short-term investments. Adjusted net income was $23.5 million, or $1.36 per diluted share.

Ligand Pharmaceuticals reported a revenue increase to $66.1 million for the third quarter of 2022, compared to $64.8 million in the same period of 2021. Net income was $0.4 million, or $0.02 per diluted share, compared to $13.7 million, or $0.80 per diluted share, for the same period in 2021. The company increased its 2022 financial guidance from continuing operations.

Ligand Pharmaceuticals reported revenue of $57.4 million for the second quarter of 2022, with royalty revenue increasing by 108% to $18.0 million. The company is progressing with the spin-off of the OmniAb business, expected to close in the fourth quarter of this year.

Ligand Pharmaceuticals reported a decrease in revenue for Q1 2022, with $45.7 million compared to $55.2 million in the prior period, primarily due to a reduction in COVID-19 related Captisol sales. Royalty revenue grew 93% to $13.7 million, and contract revenue increased by 19% to $19.9 million. The company's net loss for the quarter was $(15.4) million, or $(0.91) per share, compared to a net income of $18.1 million, or $1.05 per diluted share, for the same period in 2021. Adjusted net income was $13.1 million, or $0.76 per diluted share, compared to $24.3 million, or $1.41 per diluted share, for the same period in 2021.

Ligand reported a net loss of $(5.0) million for Q4 2021, or $(0.30) per share, compared to a net income of $5.8 million, or $0.35 per diluted share for the same period in 2020. Total revenues for the fourth quarter of 2021 were $72.5 million, compared with $70.0 million for the same period in 2020.

Ligand Pharmaceuticals reported excellent third quarter financial results, with total revenues of $64.8 million compared to $41.8 million for the same period in 2020. The company's core royalties tied to Kyprolis and Evomela continue to grow, and they have seen five approvals during the last year for new products or major markets that are now launching and are expected to fuel royalty growth next year and beyond.

Ligand Pharmaceuticals reported a record $84.7 million in total revenues for Q2 2021, driven by strong Captisol sales and contract revenue, resulting in a net income of $30.7 million, or $1.79 per diluted share.

Ligand Pharmaceuticals Incorporated reported financial results for the three months ended March 31, 2021. Total revenues for the first quarter of 2021 were $55.2 million, compared with $33.2 million for the same period in 2020. Net income for the first quarter of 2021 was $18.1 million, or $1.05 per diluted share, compared with net loss of $(24.1) million, or $(1.46) per share, for the same period in 2020.

Ligand reported strong Q4 2020 financial results with total revenues of $70.0 million, a significant increase from $27.0 million in the same period of 2019. The company's adjusted net income was $27.1 million, or $1.62 per diluted share, compared to $12.9 million, or $0.71 per diluted share, for the same period in 2019. Ligand also raised its 2021 financial guidance, expecting total revenues of approximately $291 million.

Ligand Pharmaceuticals reported a strong third quarter with total revenues of $41.8 million, driven by increased Captisol sales and contributions from recent acquisitions. Adjusted diluted EPS was $1.04, significantly higher than initial expectations. The company closed three acquisitions, including Pfenex, which is expected to contribute significantly to future financial performance.

Ligand Pharmaceuticals Incorporated reported total revenues of $41.4 million and net income of $22.1 million, or $1.32 per diluted share, for the second quarter of 2020. The company raised its 2020 financial guidance, now expecting total revenues to be approximately $165 million and adjusted diluted EPS to be $4.10.

Ligand Pharmaceuticals reported first quarter financial results with total revenues of $33.2 million, driven by strong Captisol sales, and raised its 2020 financial guidance to approximately $140 million in total revenues and $3.65 diluted EPS.

Ligand reported Q4 2019 revenues of $27.0 million, compared to $59.6 million for the same period in 2018. Net loss for the quarter was $(7.4) million, or $(0.43) per share, compared to a net loss of $(42.5) million, or $(2.02) per share, for the same period in 2018. Adjusted net income for the fourth quarter of 2019 was $12.9 million, or $0.71 per diluted share, compared with adjusted net income of $39.0 million, or $1.70 per diluted share, for the same period in 2018.